Dr Nazila Kamaly, joined Imperial College London Department of Chemisty as faculty in 2019. She was previously an Associate Professor at the Technical University of Denmark, where she was awarded a Lundbeck Fellowship to develop targeted nanomedicines for heart disease. Before that she held postdoc positions at Harvard Medical School and MIT from 2011-2016. Previous to this she did a postdoc and also her PhD in the Chemistry Department at Imperial College London and holds an MSci degree in Medicinal Chemistry from University College London. She has been developing nanomedicines, nanodiagnostics and nanotheranostics for almost 2 decades.
Research in the Kamaly group is highly multidisciplinary and uses bioinspired approaches to synthesise targeted multi-functional polymeric nanoparticles and biomaterials capable of changing their surface or core properties in response to local or up-regulated disease markers for stimuli-responsive and spatiotemporally controlled drug delivery. These nanoparticles are synthesised using bottom-up nanopolymerisation reactions. We also investigate the nanoparticle-biointerface using biomicrofluidic models with controlled environmental parameters for developing novel biomimetic drug delivery routes or testing nanoparticle physicochemical properties. This facilitates a more dynamic biological mechanistic insight between nanoparticles and target cell populations.
et al., 2022, Annexin A1 based inflammation resolving mediators and nanomedicines for inflammatory bowel disease therapy, Seminars in Immunology, Vol:61-64, ISSN:1044-5323
et al., 2022, Advancements in nanomedicines for the detection and treatment of diabetic kidney disease., Biomater Biosyst, Vol:6
Kamaly N, Farokhzad OC, Corbo C, 2022, Nanoparticle protein corona evolution: from biological impact to biomarker discovery, Nanoscale, Vol:14, ISSN:2040-3364, Pages:1606-1620
et al., 2022, Nanoconfined anti-oxidizing RAFT nitroxide radical polymer for reduction of low-density lipoprotein oxidation and foam cell formation, Nanoscale Advances, Vol:4, ISSN:2516-0230, Pages:742-753
et al., 2021, Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm, Interface Focus, Vol:12, ISSN:2042-8898